CTI receives U online drugstore .S. Patent Allowance for GlycoPolymer technology Cell Therapeutics, Inc. announced today that it provides received a Notice of Allowance from the U.S. Patent and Trademark Workplace for a patent program directed to raising the plasma half-lifestyle of therapeutic proteins and peptides by recombinantly conjugating them to a novel, non-immunogenic peptide repeat sequence. The patent and its related technology are exclusively certified to Aequus Biopharma, Inc. , many owned subsidiary of CTI, for the purpose of commercialization and development. The patent application entitled Conjugates of biologically active proteins having a altered in vivo half-life in addition has been filed in various other regions and countries, including Japan and Europe.
If uric acid increases then therefore does the chance for kidney disease. Currently, the only ways to prevent diabetic kidney disease is normally restricted control of blood sugar and blood pressure. If allopurinol can halt the increased loss of kidney function in people who have type 1 diabetes, it could be yet another safe and inexpensive method to avoid or delay kidney failing.. CU researcher awarded NIH grant to study advantage of allopurino drug in decreasing uric acid levels NIH awarding CU experts funding to study uric acid Kidney disease poses one of the greatest burdens for people coping with type 1 diabetes.